[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356642-105":59,"doc-detail-356642-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","expression-and-prognostic-impact-of-cd73-in-classical-hodgkin-lymphoma","Expression and prognostic impact of CD73 in classical Hodgkin lymphoma","","Relapsed or refractory classical Hodgkin lymphoma (cHL) poses a persistent clinical challenge, making early identification of high-risk patients essential for treatment stratification. CD73, an ectoenzyme central to adenosine production, contributes to immunosuppression and tumor progression, yet its cHL-specific role remains incompletely defined. In this retrospective case-control study, baseline CD73, CD39, and PD-L1 were assessed in 84 newly diagnosed cHL patients after first-line therapy, comparing 47 r/r cases with 37 non-r/r cases. Low CD73 expression correlated with inferior complete response rates and shorter progression-free survival; multivariate analysis confirmed it as an independent adverse prognostic factor (HR 3.321, 95% CI 1.384–7.967), supporting CD73 as a relapse-risk biomarker.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/expression-and-prognostic-impact-of-cd73-in-classical-hodgkin-lymphoma/356642/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/expression-and-prognostic-impact-of-cd73-in-classical-hodgkin-lymphoma/356642.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is early identification of high-risk patients important in relapsed or refractory classical Hodgkin lymphoma?","Question",{"text":112,"@type":113},"Relapsed or refractory cHL affects outcomes substantially, so recognizing high-risk patients early helps guide tailored treatment strategies rather than relying on uniform approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does the study evaluate regarding CD73 in classical Hodgkin lymphoma?",{"text":117,"@type":113},"The study measures baseline expression of CD73, CD39, and PD-L1 in newly diagnosed cHL patients and examines associations with treatment outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"How is low baseline CD73 expression related to patient prognosis?",{"text":121,"@type":113},"Low CD73 expression is associated with worse complete response rates and shorter progression-free survival, and multivariate analysis shows it independently predicts poorer PFS.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356642,1790584940,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Annals of Hematology (2026) 105:257  \n[https://doi.org/10.1007/s00277-026-06987-1](https://doi.org/10.1007/s00277-026-06987-1)  \nRESEARCH  \nExpression and prognostic impact of CD73 in classical Hodgkin lymphoma  \nBeichen Liu1,2 · Cuiying He2 · Haisheng Liu2 · Guangyu Ma2 · Shuo Zhang3 · Yan Liu4 · Caili Liu2 · Kexin Li2 · Yunzhe Wang2 · Yueping Liu5 · Meng Yue5 · Chang Liu5 · Xiaoxiao Wang5 · Shaoning Yin2 · Zheng Li2  \nReceived: 18 January 2026 / Accepted: 30 March 2026 / Published online: 21 April 2026 © The Author(s) 2026  \nAbstract  \nRelapsed or refractory classical Hodgkin lymphoma (cHL) remains a clinical challenge, underscoring the need for early identification of high-risk patients to guide treatment stratification. CD73, an ectoenzyme involved in adenosine production, plays a key role in immunosuppression and tumor progression. While elevated CD73 expression has been linked to poor prognosis in many cancers, its role in cHL has not been fully elucidated. In this retrospective case-control study, we evaluated the baseline expression of CD73, CD39, and PD-L1 in newly diagnosed cHL patients and explored their association with treatment outcomes. A total of 84 patients were followed after first-line therapy and retrospectively categorized into a relapsed/ refractory (r/r) group (n = 47) and a non-r/r group (n = 37) . CD73 expression was significantly lower in the r/r group compared to the non-r/r group. Patients with low CD73 expression had inferior complete response rates and shorter progression-free survival (PFS) . On multivariate analysis, low CD73 expression remained an independent adverse prognostic factor for PFS (hazard ratio: 3.321, 95% CI: 1.384–7.967) . These findings suggest that baseline CD73 expression may serve as a prognostic biomarker for relapse risk and long-term outcomes in cHL, with potential implications for individualized treatment strategies.  \nKeywords CD73 · Classical Hodgkin lymphoma · Immune checkpoint inhibitor · Prognostic factor · Relapsed/ refractory lymphoma  \nIntroduction  \nClassical Hodgkin lymphoma (cHL) originates from B cells and comprises approximately 95% of all Hodgkin lymphoma cases [1] . The World Health Organization  \nBeichen Liu and Cuiying He contributed equally to this work and are co-first authors.  \n􀀍 Zheng Li[lixixi616@sina.com](lixixi616@sina.com)  \n1 Department of Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China  \n2 Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China  \n3 Department of Breast Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China  \n4 Department of Otolaryngology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China  \n5 Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China  \n(WHO) classifies cHL into the following subtypes: nodular sclerosis (NS), mixed cellularity (MC), lymphocyterich (LR), and lymphocyte-depleted (LD) . Although most patients have favorable prognoses, approximately 20% of patients with refractory or relapsed (r/r) cHL experience negative outcomes [2] . Patients with this condition typically receive second-line chemotherapy as the initial treatment, with subsequent autologous stem cell transplantation [3] . However, disease progression occurs in approximately 50% of patients who have undergone transplantation, leading to reduced survival [4] . Thus, early identification of patients at high risk of disease recurrence or resistance is crucial for developing tailored treatment regimens to enhance therapeutic effectiveness.  \ncHL is distinguished by a complex and heterogeneous tumor microenvironment (TME) . Approximately 1–2% of the TME is composed of the distinctive multi-nucleated Reed–Sternberg (RS) tumor cells, which are surrounded by a dense network of diverse immune cells [5] . Indeed,","cbCailETim7mOZcZ","https://ap.wps.com/l/cbCailETim7mOZcZ","pdf",1042807,11,"English","# Abstract\n# Introduction","[{\"question\":\"Why is early identification of high-risk patients important in relapsed or refractory classical Hodgkin lymphoma?\",\"answer\":\"Relapsed or refractory cHL affects outcomes substantially, so recognizing high-risk patients early helps guide tailored treatment strategies rather than relying on uniform approaches.\"},{\"question\":\"What does the study evaluate regarding CD73 in classical Hodgkin lymphoma?\",\"answer\":\"The study measures baseline expression of CD73, CD39, and PD-L1 in newly diagnosed cHL patients and examines associations with treatment outcomes.\"},{\"question\":\"How is low baseline CD73 expression related to patient prognosis?\",\"answer\":\"Low CD73 expression is associated with worse complete response rates and shorter progression-free survival, and multivariate analysis shows it independently predicts poorer PFS.\"}]","Expression and prognostic impact of CD73 in classical Hodgkin lymphoma | PDF",1790126553,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ffac5a30fb8138ea224762bea06ed8df.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a4491c117a3e29abc1e238152f29790.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5ba26a1eca83abe2fbc2d915ecc1b8e.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9badbbdc3dcfe00345f9e6c51cc0fa1d.webp",980,1301]